will be removed from its pipeline. In July, H.C. Wainwright initiated coverage of AnaptysBio (NASDAQ:ANAB) with a buy rating ...

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers ...

Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market rebounded from ...

They have a few legacy molecules that they are not actively pursuing in their pipeline. These are ANB032 and Imsidolimab. They keep running these through trials and then dropping them from the ...

indicating expedited progress in the company's clinical development pipeline. AnaptysBio announced an exclusive global license agreement with Vanda Pharmaceuticals for imsidolimab, which includes ...

Guggenheim raised the firm’s price target on AnaptysBio (ANAB ... by the company’s clinical development and the rest of its pipeline assets, pointing to a higher view on the odds of success ...

(RTTNews) - AnaptysBio, Inc. (ANAB) on Monday announced that its Board of Directors has authorized a stock repurchase plan under which the company may repurchase up to $75 million of its ...

AnaptysBio plans to release further data on rosnilimab and other pipeline assets in 2025, including studies for ulcerative colitis. These developments highlight AnaptysBio's ongoing efforts in ...

https://www.tipranks.com/news/the-fly/medtronic-price-target-raised-to-93-from-89-at-truist Truist notes that AnaptysBio (ANAB) reported the “much anticipated ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports.

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.